These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14991534)

  • 1. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression.
    Dales JP; Garcia S; Carpentier S; Andrac L; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Hum Pathol; 2004 Feb; 35(2):176-83. PubMed ID: 14991534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
    Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).
    Dales JP; Garcia S; Carpentier S; Andrac L; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Taranger-Charpin C
    Br J Cancer; 2004 Mar; 90(6):1216-21. PubMed ID: 15026804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
    Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
    Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays.
    Charpin C; Dales JP; Garcia S; Carpentier S; Djemli A; Andrac L; Lavaut MN; Allasia C; Bonnier P
    Clin Cancer Res; 2004 Sep; 10(17):5815-9. PubMed ID: 15355911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
    Yao Y; Kubota T; Takeuchi H; Sato K
    Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients.
    Dales JP; Garcia S; Bonnier P; Duffaud F; Andrac-Meyer L; Ramuz O; Lavaut MN; Allasia C; Charpin C
    Am J Clin Pathol; 2003 Mar; 119(3):374-80. PubMed ID: 12645339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up.
    Charpin C; Garcia S; Bouvier C; Martini F; Andrac L; Bonnier P; Lavaut MN; Allasia C
    Am J Clin Pathol; 1997 May; 107(5):534-41. PubMed ID: 9128265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neovascularity as a prognostic marker in renal cell carcinoma.
    Bauman TM; Huang W; Lee MH; Abel EJ
    Hum Pathol; 2016 Nov; 57():98-105. PubMed ID: 27436827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.
    Dales JP; Garcia S; Bonnier P; Duffaud F; Meunier-Carpentier S; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
    Int J Oncol; 2003 Feb; 22(2):391-7. PubMed ID: 12527939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma.
    Meunier-Carpentier S; Dales JP; Djemli A; Garcia S; Bonnier P; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
    Int J Oncol; 2005 Apr; 26(4):977-84. PubMed ID: 15753992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
    Taskiran C; Erdem O; Onan A; Arisoy O; Acar A; Vural C; Erdem M; Ataoglu O; Guner H
    Int J Gynecol Cancer; 2006; 16(5):1789-93. PubMed ID: 17009973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
    Salvesen HB; Gulluoglu MG; Stefansson I; Akslen LA
    APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
    Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
    Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
    Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
    Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis.
    Dubinski W; Gabril M; Iakovlev VV; Scorilas A; Youssef YM; Faragalla H; Kovacs K; Rotondo F; Metias S; Arsanious A; Plotkin A; Girgis AH; Streutker CJ; Yousef GM
    Hum Pathol; 2012 Jul; 43(7):1037-43. PubMed ID: 22204709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
    Saad RS; Liu YL; Nathan G; Celebrezze J; Medich D; Silverman JF
    Mod Pathol; 2004 Feb; 17(2):197-203. PubMed ID: 14657950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoglin (CD105) expression in endometrial carcinoma.
    Saad RS; Jasnosz KM; Tung MY; Silverman JF
    Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.